Phase I/II Study of AZD2281 Given in Combination With Paclitaxel in Metastatic Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Triple Negative Breast Cancer|Metastatic Breast Cancer
Interventions: DRUG: AZD2281|DRUG: Paclitaxel
Sponsor: AstraZeneca